Chinese State-Backed Entities to Dispose of Stake in Tianjin Pharmaceutical Da Ren Tang Unit via Public Tender

MT Newswires

05/20

Tianjing Pharmaceutical Da Ren Tang Group's (SGX:T14) controlling shareholder, Tianjin Pharmaceutical, revealed that state-backed Chinese holding firms, SIIC Holdings and SIIC Investment Development, will sell their entire 100% stake in Shanghai Liuliguang Medical Development.

Shares of the pharmaceutical company were down under 1% in Wednesday trading.

The disposal will be carried out via a public tender on the Shanghai United Assets and Equity Exchange (SUAEE), according to a Tuesday filing with the Singapore Exchange.

Presently, Liuliguang Medical controls a 35% equity position in Jinhushen Biological Medical Science and Technology. Jinhushen, in return, holds a dominant 67% stake in the group's direct parent company, Tianjin Pharmaceutical Holdings, which retains an absolute 43.008% stake in Da Ren Tang itself.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hans/news/2636813922"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2636813922\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2636813922?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-05-20 14:02","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2636813922","market":"sg","top_or_hot":-1,"title":"Chinese State-Backed Entities to Dispose of Stake in Tianjin Pharmaceutical Da Ren Tang Unit via Public Tender","media":"MT Newswires","content":"<html><body><p> Tianjing Pharmaceutical Da Ren Tang Group's (SGX:T14) controlling shareholder, Tianjin Pharmaceutical, revealed that state-backed Chinese holding firms, SIIC Holdings and SIIC Investment Development, will sell their entire 100% stake in Shanghai Liuliguang Medical Development.</p><p>Shares of the pharmaceutical company were down under 1% in Wednesday trading.</p><p>The disposal will be carried out via a public tender on the Shanghai United Assets and Equity Exchange (SUAEE), according to a Tuesday filing with the <a href=\"https://laohu8.com/S/S68.SI\">Singapore Exchange</a>.</p><p>Presently, Liuliguang Medical controls a 35% equity position in Jinhushen Biological Medical Science and Technology. Jinhushen, in return, holds a dominant 67% stake in the group's direct parent company, Tianjin Pharmaceutical Holdings, which retains an absolute 43.008% stake in Da Ren Tang itself.</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Chinese State-Backed Entities to Dispose of Stake in Tianjin Pharmaceutical Da Ren Tang Unit via Public Tender</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nChinese State-Backed Entities to Dispose of Stake in Tianjin Pharmaceutical Da Ren Tang Unit via Public Tender\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1060499803\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires </p>\n<p class=\"h-time\">2026-05-20 14:02</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Tianjing Pharmaceutical Da Ren Tang Group's (SGX:T14) controlling shareholder, Tianjin Pharmaceutical, revealed that state-backed Chinese holding firms, SIIC Holdings and SIIC Investment Development, will sell their entire 100% stake in Shanghai Liuliguang Medical Development.</p><p>Shares of the pharmaceutical company were down under 1% in Wednesday trading.</p><p>The disposal will be carried out via a public tender on the Shanghai United Assets and Equity Exchange (SUAEE), according to a Tuesday filing with the <a href=\"https://laohu8.com/S/S68.SI\">Singapore Exchange</a>.</p><p>Presently, Liuliguang Medical controls a 35% equity position in Jinhushen Biological Medical Science and Technology. Jinhushen, in return, holds a dominant 67% stake in the group's direct parent company, Tianjin Pharmaceutical Holdings, which retains an absolute 43.008% stake in Da Ren Tang itself.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK6079","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2636813922","we_media_id":"1060499803","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2636813922","pubTimestamp":1779256978,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"MT Newswires","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1060499803","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Tianjing Pharmaceutical Da Ren Tang Group's  controlling shareholder, Tianjin Pharmaceutical, revealed that state-backed Chinese holding firms, SIIC Holdings and SIIC Investment Development, will sell their entire 100% stake in Shanghai Liuliguang Medical Development.Shares of the pharmaceutical company were down under 1% in Wednesday trading.The disposal will be carried out via a public tender on the Shanghai United Assets and Equity Exchange , according to a Tuesday filing with the Singapore Exchange.Presently, Liuliguang Medical controls a 35% equity position in Jinhushen Biological Medical Science and Technology. Jinhushen, in return, holds a dominant 67% stake in the group's direct parent company, Tianjin Pharmaceutical Holdings, which retains an absolute 43.008% stake in Da Ren Tang itself.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK6079":"制药","T14.SI":"达仁堂","BK6506":"制药与医学研究概念"},"translate_title":"中国国家支持的实体将通过公开招标出售天津制药达仁堂子公司的股份","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"T14.SI":0.9},"content_text":"Tianjing Pharmaceutical Da Ren Tang Group's (SGX:T14) controlling shareholder, Tianjin Pharmaceutical, revealed that state-backed Chinese holding firms, SIIC Holdings and SIIC Investment Development, will sell their entire 100% stake in Shanghai Liuliguang Medical Development.Shares of the pharmaceutical company were down under 1% in Wednesday trading.The disposal will be carried out via a public tender on the Shanghai United Assets and Equity Exchange (SUAEE), according to a Tuesday filing with the Singapore Exchange.Presently, Liuliguang Medical controls a 35% equity position in Jinhushen Biological Medical Science and Technology. Jinhushen, in return, holds a dominant 67% stake in the group's direct parent company, Tianjin Pharmaceutical Holdings, which retains an absolute 43.008% stake in Da Ren Tang itself.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"shareholding","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}